| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
This compound targets anaerobic bacteria and protozoan parasites. As a nitroimidazole derivative, its mechanism involves reduction of the nitro group by microbial enzymes, generating reactive intermediates that damage DNA and inhibit nucleic acid synthesis. It exhibits antibacterial and antiparasitic activities.
|
|---|---|
| ln Vitro |
In vitro, Dextrorotation nimorazole phosphate ester exhibits antimicrobial activity against anaerobic bacteria and antiprotozoal activity against parasitic infections. The compound's phosphate ester moiety may enhance solubility and bioavailability compared to the parent drug. Detailed IC50 values against specific pathogens are not extensively reported.
|
| ln Vivo |
In vivo, Dextrorotation nimorazole phosphate ester is expected to exhibit anti-anaerobic and antiparasitic efficacy based on its in vitro activity. As a fourth-generation nitroimidazole derivative, it is designed for improved tolerability and efficacy. Specific in vivo efficacy data in animal models have not been extensively reported in the available literature.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable for this antimicrobial agent. Its mechanism of action involves nitroreduction and DNA damage rather than receptor binding. Antimicrobial susceptibility testing is performed using standard broth microdilution or agar dilution methods following CLSI or EUCAST guidelines.
|
| Cell Assay |
Cellular assays for Dextrorotation nimorazole phosphate ester are conducted using anaerobic bacterial cultures and protozoan parasite cultures. Minimum inhibitory concentrations (MICs) are determined by broth microdilution. Time-kill assays are performed to assess bactericidal activity. Cytotoxicity against mammalian cells is evaluated using MTT assays.
|
| Animal Protocol |
In vivo animal studies for Dextrorotation nimorazole phosphate ester are conducted in rodent models of anaerobic bacterial infection or protozoan infection. The compound is administered via oral or parenteral routes at doses determined from pharmacokinetic studies. Efficacy endpoints include survival rate, pathogen load in target organs, and histopathological assessment.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Dextrorotation nimorazole phosphate ester are not extensively characterized. The compound has a molecular weight of 350.26 and formula C11H19N4O7P. As a phosphate ester prodrug, it is expected to be hydrolyzed to the active nitroimidazole moiety. Bioavailability and half-life data are not available in the literature.
|
| Toxicity/Toxicokinetics |
Toxicological data for Dextrorotation nimorazole phosphate ester indicate that it is well-tolerated. As a fourth-generation nitroimidazole derivative, it is designed with improved safety compared to earlier generations. Standard toxicology assessments would include evaluation of hematological parameters, organ function, and histopathology in animal models.
|
| Additional Infomation |
Dextrorotation nimorazole phosphate ester is a research-use compound not approved for clinical therapeutic applications. It represents a fourth-generation nitroimidazole derivative with anti-anaerobic and anti-parasitic activity. The compound is used in antimicrobial research to study the development of novel antibiotics and antiparasitic agents. It is for research use only and not for human therapeutic application.
|
| Molecular Formula |
C11H19N4O7P
|
|---|---|
| Molecular Weight |
350.264923334122
|
| Exact Mass |
350.099
|
| CAS # |
1124347-33-6
|
| PubChem CID |
25191609
|
| Appearance |
Pink to red solid powder
|
| LogP |
-3.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
23
|
| Complexity |
450
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC1=NC=C(N1C[C@@H](CN2CCOCC2)OP(=O)(O)O)[N+](=O)[O-]
|
| InChi Key |
CCDHHPOGWLYHAX-SNVBAGLBSA-N
|
| InChi Code |
InChI=1S/C11H19N4O7P/c1-9-12-6-11(15(16)17)14(9)8-10(22-23(18,19)20)7-13-2-4-21-5-3-13/h6,10H,2-5,7-8H2,1H3,(H2,18,19,20)/t10-/m1/s1
|
| Chemical Name |
[(2R)-1-(2-methyl-5-nitroimidazol-1-yl)-3-morpholin-4-ylpropan-2-yl] dihydrogen phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 32 mg/mL (~91.36 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8550 mL | 14.2751 mL | 28.5502 mL | |
| 5 mM | 0.5710 mL | 2.8550 mL | 5.7100 mL | |
| 10 mM | 0.2855 mL | 1.4275 mL | 2.8550 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
